The transthyretin amyloidoses: From delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug

Journal of Molecular Biology

Volumn 421, Issue 2-3, 2012, Pages 185-203

  Johnson, Steven M ^a   Connelly, Stephen ^a   Fearns, Colleen ^a   Powers, Evan T ^a   Kelly, Jeffery W ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

amyloid; kinetic stabilization; polyneuropathy; transthyretin

Indexed keywords

OLIGOMER; PREALBUMIN; TAFAMIDIS; TETRAMER;

ALZHEIMER DISEASE; AMYLOIDOSIS; FAMILIAL AMYLOID POLYNEUROPATHY; GENETIC DISORDER; HUMAN; MOLECULAR MECHANICS; MOLECULAR SIZE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN POLYMERIZATION; PROTEIN STRUCTURE; REVIEW; TRANSTHYRETIN AMYLOIDOSIS;

EID: 84861421529     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2011.12.060     Document Type: Review

References (183)

1. Connelly S., Choi S., Johnson S.M., Kelly J.W., and Wilson I.A. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses Curr. Opin. Struct. Biol. 20 2010 54 62
2. Blake C.C., Geisow M.J., Oatley S.J., Rerat B., and Rerat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å J. Mol. Biol. 121 1978 339 356
3. Hornberg A., Eneqvist T., Olofsson A., Lundgren E., and Sauer-Eriksson A.E. A comparative analysis of 23 structures of the amyloidogenic protein transthyretin J. Mol. Biol. 302 2000 649 669
4. Hamilton J.A., and Benson M.D. Transthyretin: a review from a structural perspective Cell. Mol. Life Sci. 58 2001 1491 1521
5. Schneider F., Hammarstrom P., and Kelly J.W. Transthyretin slowly exchanges subunits under physiological conditions: a convenient chromatographic method to study subunit exchange in oligomeric proteins Protein Sci. 10 2001 1606 1613
6. Monaco H.L., Rizzi M., and Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein Science 268 1995 1039 1041
7. Kopelman M., Cogan U., Mokady S., and Shinitzky M. The interaction between retinol-binding proteins and prealbumins studied by fluorescence polarization Biochim. Biophys. Acta 439 1976 449 460
8. Zanotti G., and Berni R. Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin Vitam. Horm. 69 2004 271 295
9. White J.T., and Kelly J.W. Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro Proc. Natl Acad. Sci. USA 98 2001 13019 13024
10. Purkey H.E., Dorrell M.I., and Kelly J.W. Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma Proc. Natl Acad. Sci. USA 98 2001 5566 5571
11. Bartalena L., and Robbins J. Variations in thyroid hormone transport proteins and their clinical implications Thyroid 2 1992 237 245
12. Bartalena L., and Robbins J. Thyroid hormone transport proteins Clin. Lab. Med. 13 1993 583 598
13. Johnson S.M., Wiseman R.L., Sekijima Y., Green N.S., Adamski-Werner S.L., and Kelly J.W. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses Acc. Chem. Res. 38 2005 911 921
14. Hagen G.A., and Elliott W.J. Transport of thyroid hormones in serum and cerebrospinal fluid J. Clin. Endocrinol. Metab. 37 1973 415 422
15. Herbert J., Wilcox J.N., Pham K.T., Fremeau R.T. Jr., Zeviani M., and Dwork A. Transthyretin: a choroid plexus-specific transport protein in human brain. The 1986 S. Weir Mitchell Award Neurology 36 1986 900 911
16. Foss T.R., Wiseman R.L., and Kelly J.W. The pathway by which the tetrameric protein transthyretin dissociates Biochemistry 44 2005 15525 15533
17. Foss T.R., Kelker M.S., Wiseman R.L., Wilson I.A., and Kelly J.W. Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis J. Mol. Biol. 347 2005 841 854
18. Klabunde T., Petrassi H.M., Oza V.B., Raman P., Kelly J.W., and Sacchettini J.C. Rational design of potent human transthyretin amyloid disease inhibitors Nat. Struct. Biol. 7 2000 312 321
19. Wojtczak A., Cody V., Luft J.R., and Pangborn W. Structures of human transthyretin complexed with thyroxine at 2.0 Å resolution and 3′,5′-dinitro-N-acetyl-l-thyronine at 2.2 Å resolution Acta Crystallogr., Sect. D: Biol. Crystallogr. 52 1996 758 765
20. Wojtczak A., Luft J., and Cody V. Mechanism of molecular recognition. Structural aspects of 3,3′-diiodo-l-thyroxine binding to human serum transthyretin J. Biol. Chem. 267 1992 353 357
21. Dobson C.M. Protein folding and misfolding Nature 426 2003 884 890
22. Selkoe D.J. Folding proteins in fatal ways Nature 426 2003 900 904
23. Kelly J.W. Alternative conformations of amyloidogenic proteins govern their behavior Curr. Opin. Struct. Biol. 6 1996 11 17
24. Hammarstrom P., Schneider F., and Kelly J.W. Trans-suppression of misfolding in an amyloid disease Science 293 2001 2459 2462
25. Tanzi R.E., and Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective Cell 120 2005 545 555
26. Rabinovici G.D., and Jagust W.J. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo Behav. Neurol. 21 2009 117 128
27. Coelho T., Maia L., Martins da Silva A., Waddington Cruz M., Planté-Bordeneuve V., and Lozeron P. A comprehensive evaluation of the disease-modifying effects of tafamidis in patients with transthyretin type familial amyloid polyneuropathy Neurol. 76 Supp. 4 2011 A111
28. Dyson H.J., and Wright P.E. Intrinsically unstructured proteins and their functions Nat. Rev. Mol. Cell Biol. 6 2005 197 208
29. Bradbury J. Alpha-synuclein gene triplication discovered in Parkinson's disease Lancet Neurol. 2 2003 715
30. Theuns J., and Van B.C. Alpha-synuclein gene duplications in sporadic Parkinson disease Neurology 70 2008 7 9
31. 2+ elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines J. Neurosci. 30 2010 11938 11950
32. Colon W., and Kelly J.W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro Biochemistry 31 1992 8654 8660
33. Lai Z., Colon W., and Kelly J.W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid Biochemistry 35 1996 6470 6482
34. Hurle M.R., Helms L.R., Li L., Chan W., and Wetzel R. A role for destabilizing amino acid replacements in light-chain amyloidosis Proc. Natl Acad. Sci. USA 91 1994 5446 5450
35. Booth D.R., Sunde M., Bellotti V., Robinson C.V., Hutchinson W.L., and Fraser P.E. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis Nature 385 1997 787 793
36. Guijarro J.I., Sunde M., Jones J.A., Campbell I.D., and Dobson C.M. Amyloid fibril formation by an SH3 domain Proc. Natl Acad. Sci. USA 95 1998 4224 4228
37. Wiseman R.L., Powers E.T., and Kelly J.W. Partitioning conformational intermediates between competing refolding and aggregation pathways: insights into transthyretin amyloid disease Biochemistry 44 2005 16612 16623
38. McParland V.J., Kad N.M., Kalverda A.P., Brown A., Kirwin-Jones P., and Hunter M.G. Partially unfolded states of beta(2)-microglobulin and amyloid formation in vitro Biochemistry 39 2000 8735 8746
39. Chiti F., Stefani M., Taddei N., Ramponi G., and Dobson C.M. Rationalization of the effects of mutations on peptide and protein aggregation rates Nature 424 2003 805 808
40. DuBay K.F., Pawar A.P., Chiti F., Zurdo J., Dobson C.M., and Vendruscolo M. Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains J. Mol. Biol. 341 2004 1317 1326
41. Tartaglia G.G., Pawar A.P., Campioni S., Dobson C.M., Chiti F., and Vendruscolo M. Prediction of aggregation-prone regions in structured proteins J. Mol. Biol. 380 2008 425 436
42. Goldschmidt L., Teng P.K., Riek R., and Eisenberg D. Identifying the amylome, proteins capable of forming amyloid-like fibrils Proc. Natl Acad. Sci. USA 107 2010 3487 3492
43. Fernandez-Escamilla A.M., Rousseau F., Schymkowitz J., and Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins Nat. Biotechnol. 22 2004 1302 1306
44. Amaducci L., and Tesco G. Aging as a major risk for degenerative diseases of the central nervous system Curr. Opin. Neurol. 7 1994 283 286
45. Morimoto R.I. Stress, aging, and neurodegenerative disease N. Engl. J. Med. 355 2006 2254 2255
46. Balch W.E., Morimoto R.I., Dillin A., and Kelly J.W. Adapting proteostasis for disease intervention Science 319 2008 916 919
47. Cohen E., Paulsson J.F., Blinder P., Burstyn-Cohen T., Du D., and Estepa G. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice Cell 139 2009 1157 1169
48. Powers E.T., Morimoto R.I., Dillin A., Kelly J.W., and Balch W.E. Biological and chemical approaches to diseases of proteostasis deficiency Annu. Rev. Biochem. 78 2009 959 991
49. Cohen E., Bieschke J., Perciavalle R.M., Kelly J.W., and Dillin A. Opposing activities protect against age-onset proteotoxicity Science 313 2006 1604 1610
50. Hammarstrom P., Jiang X., Hurshman A.R., Powers E.T., and Kelly J.W. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity Proc. Natl Acad. Sci. USA 99 2002 16427 16432
51. Kelly J.W., Colon W., Lai Z., Lashuel H.A., McCulloch J., and McCutchen S.L. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid Adv. Protein Chem. 50 1997 161 181
52. McCutchen S.L., Lai Z., Miroy G.J., Kelly J.W., and Colon W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease Biochemistry 34 1995 13527 13536
53. McCutchen S.L., Colon W., and Kelly J.W. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity Biochemistry 32 1993 12119 12127
54. Brignull H.R., Morley J.F., Garcia S.M., and Morimoto R.I. Modeling polyglutamine pathogenesis in C. elegans Methods Enzymol. 412 2006 256 282
55. Morley J.F., Brignull H.R., Weyers J.J., and Morimoto R.I. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans Proc. Natl Acad. Sci. USA 99 2002 10417 10422
56. Morley J.F., and Morimoto R.I. Regulation of longevity in Caenorhabditis elegans by heat shock factor and molecular chaperones Mol. Biol. Cell 15 2004 657 664
57. Westermark P., Sletten K., Johansson B., and Cornwell G.G. Fibril in senile systemic amyloidosis is derived from normal transthyretin Proc. Natl Acad. Sci. USA 87 1990 2843 2845
58. Cornwell G.G. III, Sletten K., Johansson B., and Westermark P. Evidence that the amyloid fibril protein in senile systemic amyloidosis is derived from normal prealbumin Biochem. Biophys. Res. Commun. 154 1988 648 653
59. Coelho T. Familial amyloid polyneuropathy: new developments in genetics and treatment Curr. Opin. Neurol. 9 1996 355 359
60. Jacobson D.R., Pastore R.D., Yaghoubian R., Kane I., Gallo G., Buck F.S., and Buxbaum J.N. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans N. Engl. J. Med. 336 1997 466 473
61. Reixach N., Deechongkit S., Jiang X., Kelly J.W., and Buxbaum J.N. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture Proc. Natl Acad. Sci. USA 101 2004 2817 2822
62. Saraiva M.J., Birken S., Costa P.P., and Goodman D.S. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin) J. Clin. Invest. 74 1984 104 119
63. Saraiva M.J., Costa P.P., Birken S., and Goodman D.S. Presence of an abnormal transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy Trans. Assoc. Am. Phys. 96 1983 261 270
64. Sousa M.M., and Saraiva M.J. Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling Prog. Neurobiol. 71 2003 385 400
65. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves Brain 75 1952 408 427
66. Jacobson D.R., McFarlin D.E., Kane I., and Buxbaum J.N. Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement Hum. Genet. 89 1992 353 356
67. Soares M., Buxbaum J., Sirugo G., Coelho T., Sousa A., Kastner D., and Joao Saraiva M. Genetic anticipation in Portuguese kindreds with familial amyloidotic polyneuropathy is unlikely to be caused by triplet repeat expansions Hum. Genet. 104 1999 480 485
68. Saraiva M.J.M. Transthyretin mutations in health and disease Hum. Mutat. 5 1995 191 196
69. Connors L.H., Richardson A.M., Theberge R., and Costello C.E. Tabulation of transthyretin (TTR) variants as of 1/1/2000 Amyloid 7 2000 54 69
70. Sekijima Y., Wiseman R.L., Matteson J., Hammarstrom P., Miller S.R., and Sawkar A.R. The biological and chemical basis for tissue-selective amyloid disease Cell 121 2005 73 85
71. Hammarstrom P., Sekijima Y., White J.T., Wiseman R.L., Lim A., and Costello C.E. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry 42 2003 6656 6663
72. Sekijima Y., Hammarstrom P., Matsumura M., Shimizu Y., Iwata M., and Tokuda T. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology Lab. Invest. 83 2003 409 417
73. Buxbaum J.N. Transthyretin and the transthyretin amyloidoses V.N. Uversky, A.L. Fink, Protein Misfolding, Aggregation, and Conformational Diseases: Part B. Molecular Mechanisms of Conformational Diseases 2007 Springer Science New York, NY 259 283
74. Benson M.D. Familial amyloidotic polyneuropathy Trends Biochem. Sci. 12 1989 88 92
75. Ando Y., and Suhr O.B. Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP) Amyloid 5 1998 288 300
76. Sousa M.M., Cardoso I., Fernandes R., Guimaraes A., and Saraiva M.J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates Am. J. Pathol. 159 2001 1993 2000
77. Hou X., Aguilar M.I., and Small D.H. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration FEBS J. 274 2007 1637 1650
78. Bourgault S., Solomon J.P., Reixach N., and Kelly J.W. Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion Biochemistry 50 2011 1001 1015
79. Bourgault S., Choi S., Buxbaum J.N., Kelly J.W., Price J.L., and Reixach N. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs Biochem. Biophys. Res. Commun. 410 2011 707 713
80. Zeldenrust S.R., and Benson M.D. Familial and senile amyloidosis caused by transthyretin M. Ramirez-Alvarado, J.W. Kelly, C.M. Dobson, Protein Misfolding Diseases 2010 John Wiley and Sons, Inc. New York, NY 795 815
81. Ng B., Connors L.H., Davidoff R., Skinner M., and Falk R.H. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis Arch. Intern. Med. 165 2005 1425 1429
82. Pepys M.B. Amyloidosis M. Samter, Immunological Diseases Vol. 1 1988 Little, Brown and Company Boston, MA 631 674
83. Westermark P., Bergstrom J., Solomon A., Murphy C., and Sletten K. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations Amyloid 10 2003 48 54
84. Hurshman A.R., White J.T., Powers E.T., and Kelly J.W. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization Biochemistry 43 2004 7365 7381
85. Powers E.T., and Powers D.L. The kinetics of nucleated polymerizations at high concentrations: amyloid fibril formation near and above the supercritical concentration Biophys. J. 91 2006 122 132
86. Ferrone F. Analysis of protein aggregation kinetics Methods. Enzymol. 309 1999 256 274
87. Wolfe M.S. Structure, mechanism and inhibition of γ-secretase and presenilin-like proteases Biol. Chem. 391 2010 839 847
88. John V., Beck J.P., Bienkowski M.J., Sinha S., and Heinrikson R.L. Human beta-secretase (BACE) and BACE inhibitors J. Med. Chem. 46 2003 4625 4630
89. Sambamurti K., Greig N.H., Utsuki T., Barnwell E.L., Sharma E., and Mazell C. Targets for AD treatment: conflicting messages from gamma-secretase inhibitors J. Neurochem. 117 2011 359 374
90. Lemere C.A., and Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat. Rev. Neurol. 6 2010 108 119
91. Schenk D. Opinion: Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning Nat. Rev. Neurosci. 3 2002 824 828
92. Schenk D. Hopes remain for an Alzheimer's vaccine Nature 431 2004 398
93. Comenzo R.L. Current and emerging views and treatments of systemic immunoglobulin light-chain (AL) amyloidosis Contrib. Nephrol. 153 2007 195 210
94. Gertz M.A. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management Am. J. Hematol. 86 2011 181 186
95. Kastritis E., Anagnostopoulos A., Roussou M., Toumanidis S., Pamboukas C., and Migkou M. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone Haematologica 92 2007 1351 1358
96. Kastritis E., Wechalekar A.D., Dimopoulos M.A., Merlini G., Hawkins P.N., and Perfetti V. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis J. Clin. Oncol. 28 2010 1031 1037
97. Sitia R., Palladini G., and Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 92 2007 1302 1307
98. Holmgren G., Ericzon B.G., Groth C.G., Steen L., Suhr O., and Andersen O. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis Lancet 341 1993 1113 1116
99. Herlenius G., Wilczek H.E., Larsson M., and Ericzon B.G. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry Transplantation 77 2004 64 71
100. Ando Y., Tashima K., Tanaka Y., Nakazato M., Ericzon B.G., and Duraj F.F. Treatment of a Japanese patient with familial amyloidotic polyneuropathy with orthotopic liver transplantation Intern. Med. 33 1994 730 732
101. Holmgren G., Steen L., Ekstedt J., Groth C.G., Ericzon B.G., and Eriksson S. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-Met30) Clin. Genet. 40 1991 242 246
102. Hornsten R., Wiklund U., Olofsson B.O., Jensen S.M., and Suhr O.B. Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients Transplantation 78 2004 112 116
103. Olofsson B.O., Backman C., Karp K., and Suhr O.B. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type Transplantation 73 2002 745 751
104. Liepnieks J.J., Zhang L.Q., and Benson M.D. Progression of transthyretin amyloid neuropathy after liver transplantation Neurology 75 2010 324 327
105. Dubrey S.W., Burke M.M., Hawkins P.N., and Banner N.R. Cardiac transplantation for amyloid heart disease: the United Kingdom experience J. Heart Lung Transplant. 23 2004 1142 1153
106. Falk R.H. Diagnosis and management of the cardiac amyloidoses Circulation 112 2005 2047 2060
107. Ruygrok P.N., Gane E.J., McCall J.L., Chen X.Z., Haydock D.A., and Munn S.R. Combined heart and liver transplantation for familial amyloidosis Intern. Med. J. 31 2001 66 67
108. Benson M.D., Kluve-Beckerman B., Zeldenrust S.R., Siesky A.M., Bodenmiller D.M., Showalter A.D., and Sloop K.W. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides Muscle Nerve 33 2006 609 618
109. Benson M.D., Smith R.A., Hung G., Kluve-Beckerman B., Showalter A.D., Sloop K.W., and Monia B.P. Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment Amyloid 17 2010 43 49
110. Buxbaum J.N., Ye Z., Reixach N., Friske L., Levy C., and Das P. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity Proc. Natl Acad. Sci. USA 105 2008 2681 2686
111. Li X., Masliah E., Reixach N., and Buxbaum J.N. Neuronal production of transthyretin in human and murine Alzheimer's disease: is it protective? J. Neurosci. 31 2011 12483 12490
112. Sah D.W.Y. Lipid Formulated Compositions and Methods for Inhibiting Expression of Transthyretin (TTR) 2011 Alnylam Pharmaceuticals, Inc. USA (Patent WO/2011/056883), pp. 150
113. Kelly J.W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways Curr. Opin. Struct. Biol. 8 1998 101 106
114. Hammarstrom P., Wiseman R.L., Powers E.T., and Kelly J.W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics Science 299 2003 713 716
115. Chan P.H., Pardon E., Menzer L., De Genst E., Kumita J.R., and Christodoulou J. Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils Biochemistry 47 2008 11041 11054
116. Miroy G.J., Lai Z., Lashuel H.A., Peterson S.A., Strang C., and Kelly J.W. Inhibiting transthyretin amyloid fibril formation via protein stabilization Proc. Natl Acad. Sci. USA 93 1996 15051 15056
117. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., and Viola K.L. Synaptic targeting by Alzheimer's-related amyloid beta oligomers J. Neurosci. 24 2004 10191 10200
118. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., and Liosatos M. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins Proc. Natl Acad. Sci. USA 95 1998 6448 6453
119. Lashuel H.A., Hartley D., Petre B.M., Walz T., and Lansbury P.T. Jr Neurodegenerative disease: amyloid pores from pathogenic mutations Nature 418 2002 291
120. Sousa M.M., Fernandes R., Palha J.A., Taboada A., Vieira P., and Saraiva M.J. Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro Am. J. Pathol. 161 2002 1935 1948
121. Rydh A., Suhr O., Hietala S.O., Ahlstrom K.R., Pepys M.B., and Hawkins P.N. Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation Eur. J. Nucl. Med. 25 1998 709 713
122. Jiang X., Smith C.S., Petrassi H.M., Hammarstrom P., White J.T., Sacchettini J.C., and Kelly J.W. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured Biochemistry 40 2001 11442 11452
123. Lai Z., McCulloch J., Lashuel H.A., and Kelly J.W. Guanidine hydrochloride-induced denaturation and refolding of transthyretin exhibits a marked hysteresis: equilibria with high kinetic barriers Biochemistry 36 1997 10230 10239
124. Hammarstrom P., Jiang X., Deechongkit S., and Kelly J.W. Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy Biochemistry 40 2001 11453 11459
125. Lee J., Culyba E.K., Powers E.T., and Kelly J.W. Amyloid-beta forms fibrils by nucleated conformational conversion of oligomers Nat. Chem. Biol. 7 2011 602 609
126. Lashuel H.A., Lai Z., and Kelly J.W. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation Biochemistry 37 1998 17851 17864
127. Lashuel H.A., Wurth C., Woo L., and Kelly J.W. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions Biochemistry 38 1999 13560 13573
128. Hurshman Babbes A.R., Powers E.T., and Kelly J.W. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis Biochemistry 47 2008 6969 6984
129. Colon W., Lai Z., McCutchen S.L., Miroy G.J., Strang C., and Kelly J.W. FAP mutations destabilize transthyretin facilitating conformational changes required for amyloid formation Ciba Found. Symp. 199 1996 228 238 discussion 239-242
130. Jiang X., Buxbaum J.N., and Kelly J.W. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis Proc. Natl Acad. Sci. USA 98 2001 14943 14948
131. Trivella D.B., Bleicher L., Palmieri Lde C., Wiggers H.J., Montanari C.A., and Kelly J.W. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding J. Struct. Biol. 170 2010 522 531
132. Wiseman R.L., Green N.S., and Kelly J.W. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis Biochemistry 44 2005 9265 9274
133. Quintas A., Saraiva M.J., and Brito R.M. The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis J. Biol. Chem. 274 1999 32943 32949
134. Palaninathan S.K., Mohamedmohaideen N.N., Snee W.C., Kelly J.W., and Sacchettini J.C. Structural insight into pH-induced conformational changes within the native human transthyretin tetramer J. Mol. Biol. 382 2008 1157 1167
135. Liu K., Cho H.S., Hoyt D.W., Nguyen T.N., Olds P., Kelly J.W., and Wemmer D.E. Deuterium-proton exchange on the native wild-type transthyretin tetramer identifies the stable core of the individual subunits and indicates mobility at the subunit interface J. Mol. Biol. 303 2000 555 565
136. Liu K., Cho H.S., Lashuel H.A., Kelly J.W., and Wemmer D.E. A glimpse of a possible amyloidogenic intermediate of transthyretin Nat. Struct. Biol. 7 2000 754 757
137. Liu K., Kelly J.W., and Wemmer D.E. Native state hydrogen exchange study of suppressor and pathogenic variants of transthyretin J. Mol. Biol. 320 2002 821 832
138. Coelho T., Carvalho M., Saraiva M.J., Alves I., Almeida M.R., and Costa P.P. A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR MET 30 and TTR MET 119 J. Rheumatol. 20 1993 179
139. Coelho T., Chorao R., Sausa A., Alves I., Torres M.F., and Saraiva M.J. Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy Neuromusc. Disord. 6 1996 27
140. Damas A.M., Lamzin V., Domingues F., Sebastiao M.P., and Saraiva M.J. The crystal structure of [Met30]/[Met119] variant transthyretin - the stabilizing effects introduced by a benign mutation in an amyloidogenic variant 8th International Symposium on Amyloidosis, Rochester, MN 1998
141. Schormann N., Murrell J.R., and Benson M.D. Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: new model for amyloid fibril formation Amyloid 5 1998 175 187
142. Wiseman R.L., Johnson S.M., Kelker M.S., Foss T., Wilson I.A., and Kelly J.W. Kinetic stabilization of an oligomeric protein by a single ligand binding event J. Am. Chem. Soc. 127 2005 5540 5551
143. Razavi H., Palaninathan S.K., Powers E.T., Wiseman R.L., Purkey H.E., and Mohamedmohaideen N.N. Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action Angew. Chem. Int. Ed. 42 2003 2758 2761
144. Baures P.W., Peterson S.A., and Kelly J.W. Discovering transthyretin amyloid fibril inhibitors by limited screening Bioorg. Med. Chem. 6 1998 1389 1401
145. Alhamadsheh M.M., Connelly S., Cho A., Reixach N., Powers E.T., and Pan D.W. Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity Sci. Transl. Med. 3 2011 97ra81
146. Choi S., and Kelly J.W. A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin Bioorg. Med. Chem. 19 2011 1505 1514
147. Reixach N., Adamski-Werner S.L., Kelly J.W., Koziol J., and Buxbaum J.N. Cell based screening of inhibitors of transthyretin aggregation Biochem. Biophys. Res. Commun. 348 2006 889 897
148. McCammon M.G., Scott D.J., Keetch C.A., Greene L.H., Purkey H.E., and Petrassi H.M. Screening transthyretin amyloid fibril inhibitors: characterization of novel multiprotein, multiligand complexes by mass spectrometry Structure 10 2002 851 863
149. Baures P.W., Oza V.B., Peterson S.A., and Kelly J.W. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid Bioorg. Med. Chem. 7 1999 1339 1347
150. Oza V.B., Petrassi H.M., Purkey H.E., and Kelly J.W. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors Bioorg. Med. Chem. Lett. 9 1999 1 6
151. Petrassi H.M., Klabunde T., Sacchettini J., and Kelly J.W. Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors J. Am. Chem. Soc. 122 2000 2178 2192
152. Green N.S., Palaninathan S.K., Sacchettini J.C., and Kelly J.W. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization J. Am. Chem. Soc. 125 2003 13404 13414
153. Adamski-Werner S.L., Palaninathan S.K., Sacchettini J.C., and Kelly J.W. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis J. Med. Chem. 47 2004 355 374
154. Purkey H.E., Palaninathan S.K., Kent K.C., Smith C., Safe S.H., Sacchettini J.C., and Kelly J.W. Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity Chem. Biol. 11 2004 1719 1728
155. Johnson S.M., Petrassi H.M., Palaninathan S.K., Mohamedmohaideen N.N., Purkey H.E., and Nichols C. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation J. Med. Chem. 48 2005 1576 1587
156. Razavi H., Powers E.T., Purkey H.E., Adamski-Werner S.L., Chiang K.P., Dendle M.T., and Kelly J.W. Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors Bioorg. Med. Chem. Lett. 15 2005 1075 1078
157. Petrassi H.M., Johnson S.M., Purkey H.E., Chiang K.P., Walkup T., and Jiang X. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state J. Am. Chem. Soc. 127 2005 6662 6671
158. Green N.S., Foss T.R., and Kelly J.W. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis Proc. Natl Acad. Sci. USA 102 2005 14545 14550
159. Johnson S.M., Connelly S., Wilson I.A., and Kelly J.W. Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors J. Med. Chem. 51 2008 260 270
160. Johnson S.M., Connelly S., Wilson I.A., and Kelly J.W. Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies J. Med. Chem. 51 2008 6348 6358
161. Johnson S.M., Connelly S., Wilson I.A., and Kelly J.W. Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies J. Med. Chem. 52 2009 1115 1125
162. Choi S., Connelly S., Reixach N., Wilson I.A., and Kelly J.W. Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma Nat. Chem. Biol. 6 2010 133 139
163. Choi S., Reixach N., Connelly S., Johnson S.M., Wilson I.A., and Kelly J.W. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity J. Am. Chem. Soc. 132 2010 1359 1370
164. Choi S., Ong D.S., and Kelly J.W. A stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate J. Am. Chem. Soc. 132 2010 16043 16051
165. Peterson S.A., Klabunde T., Lashuel H.A., Purkey H., Sacchettini J.C., and Kelly J.W. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation Proc. Natl Acad. Sci. USA 95 1998 12956 12960
166. Miller S.R., Sekijima Y., and Kelly J.W. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants Lab. Invest. 84 2004 545 552
167. Kolstoe S.E., Mangione P.P., Bellotti V., Taylor G.W., Tennent G.A., and Deroo S. Trapping of palindromic ligands within native transthyretin prevents amyloid formation Proc. Natl Acad. Sci. USA 107 2010 20483 20488
168. Almeida M.R., Gales L., Damas A.M., Cardoso I., and Saraiva M.J. Small
169. Almeida M.R., Macedo B., Cardoso I., Valencia G., Arsequell G., Planas A., and Saraiva M.J. Effects of a new diflunisal derivative on transthyretin binding and stabilization in serum from FAP patients 10th International Symposium on Amyloidosis, Tours, France 2004
170. Mairal T., Arsequell G., Valencia G., Dolado I., Nieto J., and Planas A. Identification of new diflunisal derivatives as potent in vitro transthyretin fibril inhibitors 10th International Symposium on Amyloidosis, Tours, France 2004
171. Morais-de-Sa E., Pereira P.J.B., Saraiva M.J., and Damas A.M. The binding of diethylstilbestrol to transthyretin - a crystallographic model 10th International Symposium on Amyloidosis, Tours, France 2004
172. Vilaro M., Arsequell G., Valencia G., Ballesteros A., Barluenga J., and Nieto J. Reengineering TTR amyloid inhibition properties of diflunisal 11th International Symposium on Amyloidosis, Woods Hole, MA 2006
173. Gupta S., Chhibber M., Sinha S., and Surolia A. Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates J. Med. Chem. 50 2007 5589 5599
174. Julius R.L., and Hawthorne M.F. Amyloid disease prevention by transthyretin native state complexation with carborane derivatives lacking cyclooxygenase inhibition Drug News Perspect. 21 2008 258 266
175. Pullakhandam R., Srinivas P.N.B.S., Nair M.K., and Reddy G.B. Binding and stabilization of transthyretin by curcumin Arch. Biochem. Biophys. 485 2009 115 119
176. Raghu P., Reddy G.B., and Sivakumar B. Inhibition of transthyretin amyloid fibril formation by 2,4-dinitrophenol through tetramer stabilization Arch. Biochem. Biophys. 400 2002 43 47
177. Simoes C.J., Mukherjee T., Jackson R.M., and Brito R.M. Functional binders for non-specific binding: evaluation of virtual screening methods for the elucidation of novel transthyretin amyloid inhibitors 240th ACS National Meeting, Boston, MA 2010
178. Ferguson R.N., Edelhoch H., Saroff H.A., and Robbins J. Negative cooperativity in the binding of thyroxine to human serum prealbumin Biochemistry 14 1975 282 289
179. Sekijima Y., Kelly J.W., and Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses Curr. Pharm. Des. 14 2008 3219 3230
180. Sekijima Y., Dendle M.A., and Kelly J.W. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis Amyloid 13 2006 236 249
181. Tojo K., Sekijima Y., Kelly J.W., and Ikeda S. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis Neurosci. Res. 56 2006 441 449
182. Nowak R.J., Cuny G.D., Choi S., Lansbury P.T., and Ray S.S. Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods J. Med. Chem. 53 2010 2709 2718
183. Woods L.A., Platt G.W., Hellewell A.L., Hewitt E.W., Homans S.W., Ashcroft A.E., and Radford S.E. Ligand binding to distinct states diverts aggregation of an amyloid-forming protein Nat. Chem. Biol. 7 2011 730 739